Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Public ClinicalTrials.gov record NCT00140075. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Study identification
- NCT ID
- NCT00140075
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 606 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2000 (Type not available)
- Primary completion
- Aug 2006 (Actual)
- Completion
- Aug 2006 (Actual)
- Last update posted
- May 26, 2011
2000 – 2006
United States locations
- U.S. sites
- 54
- U.S. states
- 23
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Mobile | Alabama | 36608 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85712 | — |
| Pfizer Investigational Site | Bakersfield | California | 93309 | — |
| Pfizer Investigational Site | Berkeley | California | 94704 | — |
| Pfizer Investigational Site | Fountain Valley | California | 92708 | — |
| Pfizer Investigational Site | Fountian Valley | California | 92708 | — |
| Pfizer Investigational Site | Gilroy | California | 95020 | — |
| Pfizer Investigational Site | Poway | California | 92064 | — |
| Pfizer Investigational Site | Soquel | California | 95073 | — |
| Pfizer Investigational Site | Colorado Springs | Colorado | 80907 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32224 | — |
| Pfizer Investigational Site | Jacksonville | Florida | — | — |
| Pfizer Investigational Site | Kissimmee | Florida | 34741 | — |
| Pfizer Investigational Site | Lake Worth | Florida | 33461 | — |
| Pfizer Investigational Site | Lecanto | Florida | 34461 | — |
| Pfizer Investigational Site | Miami | Florida | 33176 | — |
| Pfizer Investigational Site | Miami Shores | Florida | 33138 | — |
| Pfizer Investigational Site | Port Saint Lucie | Florida | 34952 | — |
| Pfizer Investigational Site | Tampa | Florida | 33607 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30309 | — |
| Pfizer Investigational Site | Macon | Georgia | 31201 | — |
| Pfizer Investigational Site | Belleville | Illinois | 62226 | — |
| Pfizer Investigational Site | Skokie | Illinois | 60076 | — |
| Pfizer Investigational Site | Baton Rouge | Louisiana | 70809 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | — | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21236 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21237 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02120 | — |
| Pfizer Investigational Site | Harper Woods | Michigan | — | — |
| Pfizer Investigational Site | Hattiesburg | Mississippi | 39401 | — |
| Pfizer Investigational Site | Jackson | Mississippi | 39202 | — |
| Pfizer Investigational Site | Mount Holly | New Jersey | 08060 | — |
| Pfizer Investigational Site | Willingboro | New Jersey | 08046 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Pfizer Investigational Site | Brooklyn | New York | 11235 | — |
| Pfizer Investigational Site | Great Neck | New York | 11021' | — |
| Pfizer Investigational Site | Staten Island | New York | 10310 | — |
| Pfizer Investigational Site | Burlington | North Carolina | 27216 | — |
| Pfizer Investigational Site | Greenville | North Carolina | 27854 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27607 | — |
| Pfizer Investigational Site | Lawton | Oklahoma | 73505 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Pfizer Investigational Site | Lemoyne | Pennsylvania | 17043 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19106 | — |
| Pfizer Investigational Site | Charleston | South Carolina | — | — |
| Pfizer Investigational Site | Columbia | South Carolina | 29201 | — |
| Pfizer Investigational Site | Germantown | Tennessee | 38138 | — |
| Pfizer Investigational Site | Knoxville | Tennessee | 37923 | — |
| Pfizer Investigational Site | Corpus Christi | Texas | 78412 | — |
| Pfizer Investigational Site | Tyler | Texas | 11937 | — |
| Pfizer Investigational Site | Arlington | Virginia | 22205 | — |
| Pfizer Investigational Site | Portsmouth | Virginia | 23704 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23226 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00140075, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2011 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00140075 live on ClinicalTrials.gov.